To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This study is to evaluate 24-week efficacy and 52 week immunogenicity of subcutaneous Eporon versus Epoetin Alfa (Eprex) in the treatment of anemia associated with chronic renal failure in pre-dialysis patients. A total of 214 patients will be enrolled in Turkey.
Epistemonikos ID: 9fe09902cb4eaa5c8f517a30650b169e90ecd2d1
First added on: May 21, 2024